Labiotech.eu

News and Trends 13 May 2022

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […]

May 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 May 2022

The Top European Biotech Investments in April 2022

Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […]

May 12, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 10 May 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

The French startup creator eureKARE has set up a special purposes acquisition company (SPAC) with the ambition to merge multiple European contract development and manufacturing organizations into a heavyweight serving developers of gene therapies, protein drugs, and microbiome therapeutics. Over the last few years, record levels of funding have flowed into the biotech industry, particularly […]

May 10, 2022 - 4 minutesmins - By Jonathan Smith

In Depth 9 May 2022

Exosome Therapy: Borrowing from Nature’s Toolbox

In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […]

May 9, 2022 - 11 minutesmins - By Farhan Mitha

News and Trends 6 May 2022

Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast

Tapping into the increasingly sophisticated market for meat alternatives, the Swedish synthetic biology startup Melt&Marble has raised €5M in seed financing to fund the development of a fermented fat ingredient that mimics the complex properties of beef fat. Companies are racing to enhance the flavor, melt, and mouthfeel of meat alternative products such as plant-based […]

May 6, 2022 - 4 minutesmins - By Anita Chakraverty

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […]

May 3, 2022 - 3 minutesmins - By Jonathan Smith

stephanie bewick destiny pharma chief business officer

Expert Advice 2 May 2022

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […]

May 2, 2022 - 5 minutesmins - By Victor Kotsev

News and Trends 29 Apr 2022

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

The Danish National Genome Center has teamed up with the UK firm Lifebit to improve the access and sharing of genomic data as the nation moves towards the adoption of personalized medicine. Personalized medicine is capturing the attention of healthcare authorities across the world. By harvesting genome sequences from patient populations, researchers can mine vast […]

April 29, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 28 Apr 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]

April 28, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 27 Apr 2022

Cancer Research UK Deploys €700M to Foster Oncology Startups

In a show of strength after an income squeeze during the Covid-19 pandemic, the charity Cancer Research UK has dedicated €711M (£600M) to setting up a new innovation arm and seed fund designed to speed up the commercialization of oncology innovation. For decades, Cancer Research UK (CRUK) has played a pivotal role in nurturing advances […]

April 27, 2022 - 4 minutesmins - By Jonathan Smith

cardiovascular disease heart attack forcefield therapeutics

News and Trends 25 Apr 2022

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […]

April 25, 2022 - 4 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

The Top European Biotech Investments in April 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

Exosome Therapy: Borrowing from Nature’s Toolbox

Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Tubulis Rides Investment Wave in ADCs with €60M Series B

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

Cancer Research UK Deploys €700M to Foster Oncology Startups

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!